Natural Product (NP) Details
General Information of the NP (ID: NP9279) | |||||
---|---|---|---|---|---|
Name |
Genistein
|
||||
Synonyms |
Bonistein; GEN; Genestein; Genisteol; Genisterin; Prunetol; Sophoricol; Differenol A; G 6649; G10000; IN1327; NPI 031L; STO514; TNP00151; GENISTEIN (ENDOCRINE DISRUPTER); Lactoferrin-genistein; PTI G4660 (Genistein); PTI-G4660; SIPI 807-1; C.I. 75610; SIPI-9764-I; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; ,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
Click to Show/Hide
|
||||
Species Origin | Glycine max ... | Click to Show/Hide | |||
Glycine max | |||||
Genista tinctoria | |||||
Trifolium pratense | |||||
Ixora chinensis | |||||
Disease | Prostate cancer [ICD-11: 2C82] | Phase 2 | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C15H10O5
|
||||
PubChem CID | |||||
Canonical SMILES |
C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
|
||||
InChI |
1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
|
||||
InChIKey |
TZBJGXHYKVUXJN-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 446-72-0
|
||||
ChEBI ID | |||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Selenite | Arsenical melanosis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Selenium and genistein act via different molecular mechanisms and exhibit enhanced anticancer effects. | |||||
Centchroman | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | CASP7 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Activity | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PD-2 | Molecule Info | |||
Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
MCF-10A | CVCL_0598 | Healthy | Homo sapiens | |||
4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | |||
In-vivo Model | 4T1 (7*105) cells were injected onto the left mammary fat pad of adult female BALB/c mice. | |||||
Experimental
Result(s) |
Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis. | |||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | PIK3CB | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
In-vivo Model | The exponentially growing A549 cells were harvested and a tumorigenic dose of 2.5*106 cells was injected intraperitoneally into the 4-5 week-old mice. | |||||
Experimental
Result(s) |
Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo. | |||||
Cabazitaxel | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | LNCaP C4-2 | CVCL_4782 | Prostate carcinoma | Homo sapiens | ||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
ARCaPM | Prostate cancer | Homo sapiens | ||||
In-vivo Model | PC3-luc cells (2*106) per 100L per site were injected subcutaneously in athymic nude mice (BALB/c, 6-week-old). | |||||
Experimental
Result(s) |
Genistein increases the expression of pro-apoptotic protein Bax, activates apoptotic signals, and enhances the response to cabazitaxel treatment in mCRPC cells. | |||||
Indole-3-carbinol | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. | |||||
Tamoxifen | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | ESR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. | |||||
N-(4-hydroxyphenyl) retinamide | Cervical cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | AIFM1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CAPN1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | FGF2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SK-N-BE(2) | CVCL_0528 | Neuroblastoma | Homo sapiens | ||
SH-SY5Y | CVCL_0019 | Neuroblastoma | Homo sapiens | |||
In-vivo Model | Each of neuroblastoma SK-N-BE2 and SH-SY5Y cells (6*106) in 100 ul of 1:1 mixture with Matrigel was implanted by subcutaneous (sc) injection on the flank of each mouse (six weeks-old female athymic nu/nu mice) under isoflurane anesthesia condition. | |||||
Experimental
Result(s) |
Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-N-BE2 and SH-SY5Y xenografts. | |||||
HA14-1 | Colon cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | AIFM1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CAPN1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | DIABLO | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | NMI | Molecule Info | |||
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | SK-N-BE(2) | CVCL_0528 | Neuroblastoma | Homo sapiens | ||
SH-SY5Y | CVCL_0019 | Neuroblastoma | Homo sapiens | |||
Experimental
Result(s) |
Combination of HA and GST was more effective in inducing apoptosis in both cell lines than either HA or GST alone by down-regulating survival factors and activating cysteine proteases for apoptosis. | |||||
Cetuximab | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [10] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
In-vitro Model | HSC-3 | CVCL_1288 | Tongue squamous cell carcinoma | Homo sapiens | ||
KB | CVCL_0372 | Oral squamous cell carcinoma | Homo sapiens | |||
In-vivo Model | HSC3 cells (1*107) were inoculated subcutaneously into the right flank of total eighty 6-8-week-old female BALB/c nude mice. | |||||
Experimental
Result(s) |
Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma. | |||||
1,25-dihydroxyvitamin D3 | Congenital alopecia | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [11] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CYP24A1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | VDR | Molecule Info |
Pathway MAP
|
||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Genistein potentiates the antiproliferative actions of 1,25(OH)2D3 in DU145 cells by two mechanisms: (i) an increase in the half-life of 1,25(OH)2D3 due to the direct inhibition of CYP24 enzyme activity and (ii) an amplification of the homologous up-regulation of VDR. | |||||
Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [12] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | COL11A2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
In-vivo Model | Detached H1975 cells were diluted and emulsified with medium to a final concentration of 2*107 cells/ml. The emulsion (200 uL) was inoculated subcutaneously into 4-6-week-old female nude BALB/c mice. | |||||
Experimental
Result(s) |
Genistein enhanced the antitumor effects of gefitinib in a NSCLC cell line carrying the T790M mutation. This synergistic activity may be due to increased inhibition of the downstream molecular and pro-apoptotic effects of EGFR. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [13] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Genistein enhances TRAIL-induced cancer cell death via inactivation of autophagic flux. | |||||
Topotecan | Ovarian cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [14] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Genistein-topotecan combination was significantly more efficacious in reducing LNCaP cell viability compared with either genistein or topotecan alone. | |||||
Terazosin | Prostate hyperplasia | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [15] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | NRP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
The terazosin/genistein combination was more effective in inhibiting cell growth and VEGF expression as well as inducing apoptosis of the metastatic, androgen-independent prostate cancer cell line, DU-145, than either alone. | |||||
Dexamethasone | Rheumatoid arthritis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [16] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
In-vitro Model | COLO 320 | CVCL_1989 | Colon adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
The combined effects of dexamethasone and genistein on the induction of p21 protein and activation of p21 promoter were synergistic. | |||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [17] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
In-vivo Model | MIA PaCa-2 cells (2*106 cells/100 L) were injected subcutaneously into the right flank of female nude mice aged 4-6 weeks. | |||||
Experimental
Result(s) |
Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells. | |||||
Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [18] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | MNNG/HOS Cl #5 | CVCL_0439 | Osteosarcoma | Homo sapiens | ||
Experimental
Result(s) |
Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-KappaB pathway. | |||||
Trichostatin A | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [19] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP10 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Genistein enhances the effect of trichostatin A on inhibition of A549 cell growth by increasing expression of TNF receptor-1. | |||||
Thearubigin | Acute lung injury | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [20] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
In-vitro Model | PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Thearubigin and genistein combination showed synergistic effects on human prostate tumor cell (PC-3) growth via cell cycle arrest. | |||||
Tiazofurin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [21] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Induction | Cell differentiation | ||||
In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
Experimental
Result(s) |
Tiazofurin and genistein showed synergistic action on growth inhibition and differentiation of K-562 human leukemic cells. | |||||
Trastuzumab | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [22] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | ||
Experimental
Result(s) |
Genistein significantly enhanced the antitumoral effect of trastuzumab on BT-474 breast cancer cells in vitro. | |||||
1,3-bis(2-chloroethyl)-1-nitrosourea | Hepatocellular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [23] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
Experimental
Result(s) |
Genistein at typical adult dietary plasma levels can significantly enhance the antiproliferative and cytotoxic action of BCNU. | |||||
Decitabine | Myelodysplastic syndrome | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [24] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | ||
MOLT-3 | CVCL_0624 | Adult T acute lymphoblastic leukemia | Homo sapiens | |||
L1210 | CVCL_0382 | Mouse leukemia | Mus musculus | |||
In-vivo Model | Male CD2F1 mice (24-28 g) were injested with L1210 leukemic cells intravenously into the lateral tail vein. | |||||
Experimental
Result(s) |
The combined treatment produced a synergistic loss of clonogenicity in human myeloid (HL-60) and lymphoid (MOLT-3) leukemic cell lines. | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
17-beta estradiol | Hepatocellular carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [25] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | COMT | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | CYP1A1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Genistein decreases the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Oestrogen receptor beta (ESR2) | Molecule Info | [26] | |
KEGG Pathway | Estrogen signaling pathway | Click to Show/Hide | ||
2 | Prolactin signaling pathway | |||
Pathway Interaction Database | Plasma membrane estrogen receptor signaling | Click to Show/Hide | ||
2 | Validated nuclear estrogen receptor beta network | |||
3 | Validated nuclear estrogen receptor alpha network | |||
Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
WikiPathways | SIDS Susceptibility Pathways | Click to Show/Hide | ||
2 | Ovarian Infertility Genes | |||
3 | Integrated Pancreatic Cancer Pathway | |||
4 | Nuclear Receptors |